Organigram Global Inc. (OGI) Stock Price & Analysis
Organigram Global Inc. (OGI) is trading at USD 0.92, down 1.25% today, as of October 23, 2026 at 17:48 UTC (US market open; quotes may be delayed), according to Nexqual market data.
OGI last closed at USD 0.94; today's session has ranged USD 0.92–0.95 on volume of 93,875 shares. Market capitalization is $133.33M, with a 52-week range of USD 0.85–2.24 (NMS). Source: Nexqual, retrieved October 23, 2026 at 17:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OGI.md
Key facts (OGI)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts).
- Total return with dividends: 1Y -46.8% vs S&P 500 +14.4%; 5Y -89.5% vs S&P 500 +77.1%.
- Next earnings: 2026-08-11, EPS estimate USD 0.01, revenue estimate $121M.
Analysts (OGI)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts.
Total return (dividends reinvested) (OGI)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -46.8% | -89.5% |
| S&P 500 (SPY) | +14.4% | +77.1% |
| Per year | -46.9% | -36.4% |
| Volatility (annualized) | 56.8% | 62.6% |
| Max drawdown | -58.7% (Dec 2025→Jul 2026) | -90.3% (Nov 2021→Jul 2026) |
OGI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.01 | $0.00 | +206.9% | $120.7M | 3 |
| Next quarter (ends Dec 2026) | $0.01 | $0.00 | — | $111.5M | 1 |
| Current fiscal year (ends Sep 2026) | $0.44 | $0.07 | +565.2% | $349.8M | 1 |
| Next fiscal year (ends Sep 2027) | $0.02 | $0.02 | +9.1% | $458.1M | 1 |
OGI options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Dec 18, 2026 | 56 | 89.2% | ±27.2% |
| Mar 19, 2027 | 147 | 142.9% | ±40.8% |
30-day implied volatility 36.4% vs 37.7% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 17:48 UTC)
| Price | USD 0.92 |
|---|---|
| Change | ▼ 1.25% (down) |
| Previous Close | USD 0.94 |
| Open | USD 0.93 |
| Day Range | USD 0.92 – 0.95 |
| 52-Week Range | USD 0.85 – 2.24 |
| Volume | 93,875 shares |
| Market Cap | $133.33M |
| Exchange | NMS |
Technical Analysis (OGI)
Nexqual's technical model rates OGI "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 17:48 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.18 (neutral) |
| vs SMA50 | Below (USD 1.08) |
| MACD | -0.04 (negative) |
Analyst Ratings (OGI)
Wall Street analysts rate OGI "Buy" based on 5 analysts, per Nexqual as of October 23, 2026 at 17:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (OGI)
| Next Earnings Date | 2026-08-11 |
|---|---|
| Revenue Estimate | $120.65M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.55 vs est -0 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.01 ▼ miss |
| 2025-09-30 | USD -0.2 vs est -0.01 ▼ miss |
Source: Nexqual, October 23, 2026 at 17:48 UTC.
Financials & Fundamentals (OGI)
| Total Revenue | $309.18M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +49.40% |
| Gross Margin | +36.54% |
| Operating Margin | +5.04% |
| Profit Margin | +28.02% |
| ROE | +17.56% |
| Debt / Equity | 0.06 |
| Current Ratio | 2.61 |
| Total Cash | $11.67M |
| Total Debt | $31.65M |
Source: Nexqual, October 23, 2026 at 17:48 UTC.
Financial Health Score (OGI)
Nexqual rates Organigram Global Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 17:48 UTC.
| Growth | Strong — Revenue +62% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 37%, operating 5% (last 12 months) |
| Balance Sheet | Strong — CAD 12M cash vs CAD 32M debt |
| Cash Flow | Weak — Operating cash flow -CAD 29M (TTM) |
| Efficiency | Solid — ROE 18%, ROA -0.6% |
Ownership (OGI)
| Insider Ownership | +31.06% |
|---|---|
| Institutional Ownership | +6.53% |
| Shares Outstanding | 144.15M |
| Float | 97.33M |
Source: Nexqual, October 23, 2026 at 17:48 UTC.
Leadership (OGI)
Organigram Global Inc. is led by James H. Yamanaka, CEO & Director, per Nexqual as of October 23, 2026 at 17:48 UTC.
| CEO & Director | James H. Yamanaka |
|---|---|
| Executive Chairman | Peter L. Amirault |
| Chief Financial Officer | Greg Guyatt C.A. |
| President of Organigram Canada | Timothy Emberg |
| Global Chief Operating Officer | Adrian Frenzel |
Major Backers & Investors (OGI)
Notable institutional backers of Organigram Global Inc. include Amplify ETF Trust-Amplify Alternative Harvest ETF, Tidal Investments LLC, Renaissance Technologies, according to Nexqual as of October 23, 2026 at 17:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Amplify ETF Trust-Amplify Alternative Harvest ETF | 1.54% |
| Tidal Investments LLC | 1.53% |
| Renaissance Technologies | 1.02% |
| AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 0.66% |
| AdvisorShares Investments, LLC | 0.63% |
| Goldman Sachs | 0.43% |
| Morgan Stanley | 0.22% |
| Baader Bank Aktiengesellschaft | 0.18% |
Source: Nexqual, October 23, 2026 at 17:48 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.34 | ▼ 2.39% |
| HCM | HUTCHMED (China) Limited | USD 14.35 | ▲ 0.49% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▼ 3.22% |
| LQDA | Liquidia Corporation | USD 41.15 | ▲ 3.68% |
| RGC | Regencell Bioscience Holdings L | USD 8.16 | ▼ 16.82% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.32 | ▼ 2.86% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 17:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt